<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848272</url>
  </required_header>
  <id_info>
    <org_study_id>SVI-01</org_study_id>
    <nct_id>NCT04848272</nct_id>
  </id_info>
  <brief_title>Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury</brief_title>
  <official_title>Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Vincent's Institute of Medical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study investigating safety of lanadelumab administration to patients with lung injury&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the safety of inhibition of plasma kallikrein by lanadelumab&#xD;
      administration in patients with lung injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label placebo-controlled dose-escalation Phase 1 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Blood gases, pH, bicarbonate, carbon dioxide and lactic acid levels. If the participant is receiving mechanical ventilation, the ventilator settings will be constantly monitored.&#xD;
Chest X-ray, as indicated. Constant monitoring of haemodynamics (pulse rate, blood pressure) via an arterial cannula, use of vasoactive medications, and constant monitoring of ECG. Fluid balance, including urine output. Serum creatinine, electrolytes, liver function, creatinine kinase, FBE and coagulation will be measured daily or less frequently as decided by the treating team.&#xD;
If there is suspicion of infection, then appropriate samples will be taken for microbiological examination.&#xD;
Neurological function will be assessed several times per day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood bradykinin concentration</measure>
    <time_frame>0, 6, 12, and 24 hours</time_frame>
    <description>Blood bradykinin concentration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Lung Injury</condition>
  <arm_group>
    <arm_group_label>Saline control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanadelumab 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanadelumab 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanadelumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanadelumab 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanadelumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lanadelumab 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab</intervention_name>
    <description>Monoclonal antibody that targets active plasma kallikrein</description>
    <arm_group_label>Lanadelumab 100 mg</arm_group_label>
    <arm_group_label>Lanadelumab 30 mg</arm_group_label>
    <arm_group_label>Lanadelumab 300 mg</arm_group_label>
    <other_name>Takhzyro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline control</intervention_name>
    <description>Saline control</description>
    <arm_group_label>Saline control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years admitted to the ICU with primary diagnosis of lung injury. The criteria&#xD;
             for the diagnosis of lung injury include five principal elements: hypoxemia (blood&#xD;
             oxygen saturation (PaO2) ≤92% when breathing ambient air, ratio of PaO2 to the&#xD;
             fraction of inspired oxygen (FiO2) ≤300), diffuse pulmonary infiltrates on chest&#xD;
             radiographs, decreased lung compliance, and the absence of congestive heart failure.&#xD;
&#xD;
          -  Both males and females will be recruited in the proportion in which they are admitted&#xD;
             to the ICU with lung injury.&#xD;
&#xD;
          -  Arterial cannula in place as part of usual care for the measurement of blood gases.&#xD;
&#xD;
          -  Patients may or may not be intubated and mechanically ventilated.&#xD;
&#xD;
          -  Able to provide informed consent, or if unable to do so, a responsible person:&#xD;
&#xD;
        medical treatment decision maker is available (by telephone if necessary) who can be&#xD;
        approached to seek consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of lung infiltrates: pulmonary oedema, alveolar haemorrhage, adverse drug&#xD;
             reactions, radiation injury and the idiopathic pneumonitis syndrome.&#xD;
&#xD;
          -  Significant dysfunction of non-pulmonary organs in the opinion of the treating ICU&#xD;
             consultant.&#xD;
&#xD;
          -  Death is deemed imminent or inevitable or there is underlying disease with a life&#xD;
             expectancy of less than 90 days.&#xD;
&#xD;
          -  Previously enrolled in this study.&#xD;
&#xD;
          -  Enrolled in another study.&#xD;
&#xD;
          -  Usually receives home oxygen.&#xD;
&#xD;
          -  Usually receives any type of assisted ventilation at home. e.g. continuous positive&#xD;
             airway pressure for obstructive sleep apnoea.&#xD;
&#xD;
          -  Pregnant or might be pregnant. Women aged 18 to 49 are excluded unless there is&#xD;
             documented menopause, hysterectomy or surgical sterilisation, or a pregnancy test is&#xD;
             negative.&#xD;
&#xD;
          -  Objection from the treating clinician.&#xD;
&#xD;
          -  Consent refused by the patient or substitute decision maker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Institute of Medical Research</investigator_affiliation>
    <investigator_full_name>Duncan Campbell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised individual participant data (IPD) available to other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After completion of study</ipd_time_frame>
    <ipd_access_criteria>To be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

